Aligos Therapeutics Q4 net loss narrows

Reuters03-05
Aligos <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q4 net loss narrows

Overview

  • Biotechnology firm's Q4 net loss narrowed significantly compared to the previous year

  • Aligos advanced ALG-170675 into IND-enabling studies with Amoytop

Outlook

  • Aligos expects funding to last into Q3 2026

Result Drivers

  • HIGHER R&D EXPENSES: Research and development (R&D) expenses for the three months ended December 31, 2025 were $17.0 million, compared with $16.0 million for the same period of 2024.

  • LOWER GENERAL AND ADMINISTRATIVE (G&A) EXPENSES: General and administrative (G&A) expenses for the three months ended December 31, 2025 were $4.9 million, compared with $5.2 million for the same period of 2024.

Company press release: ID:nGNXDXNVG

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Net Income

-$19.88 mln

Q4 Income From Operations

-$21.81 mln

Q4 Operating Expenses

$21.98 mln

Q4 Pretax Profit

-$19.85 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Aligos Therapeutics Inc is $50.00, about 628.9% above its March 4 closing price of $6.86

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment